Loading...

Purified anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5_Pure_030206
C57BL/6 mouse splenocytes stained with purified CD4 (clone RM4-5) (filled histogram) or purified rat IgG2a, κ isotype control (open histogram).
  • RM4-5_Pure_030206
    C57BL/6 mouse splenocytes stained with purified CD4 (clone RM4-5) (filled histogram) or purified rat IgG2a, κ isotype control (open histogram).
  • RM4-5_Pure_CD4_Antibody_2_100219
    C57BL/6 mouse frozen spleen section was fixed with 4% paraformaldehyde (PFA) for 10 minutes at room temperature and blocked with 5% FBS for 30 minutes at room temperature. Then the section was stained with 10 µg/ml of purified anti-mouse CD4 (clone RM4-5), and anti-mouse CD3ε (clone 500A2) Alexa Fluor® 594 (green) overnight at 4°C, followed by 2.5 µg/mL of Alexa Fluor® 647 anti-rat IgG (clone Poly4054) (red) for two hours at room temperature. Nuclei were counterstained with DAPI (blue). The image was captured by 10X objective.
Compare all formats
Cat # Size Price Quantity Check Availability Save
100505 50 µg £21
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100506 500 µg £58
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF®, IHC-F - Verified
IHC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µl volume. For immunohistochemistry on frozen tissue sections, a concentration range of 5.0 - 10 µg/ml is suggested. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  2. Abdel-Gadir A, et al. 2019. Nat Med. 25:1164. PubMed
  3. Hu J, et al. 2019. Am J Transl Res. 3.043055556. PubMed
  4. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  5. Tersteegen A, et al. 2021. Infect Immun. 89:. PubMed
  6. Doll JR, et al. 2020. PLoS Pathog. 16:e1008296. PubMed
  7. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
  8. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  9. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  10. Bieber M, et al. 2022. Int J Mol Sci. 23: . PubMed
  11. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  12. Tomiaki C, et al. 2022. Front Immunol. 13:1014462. PubMed
  13. Claes C, et al. 2022. Alzheimers Dement. 18:1765. PubMed
  14. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  15. Bellut M, et al. 2023. J Neuroinflammation. 20:4. PubMed
  16. Kondo H, et al. 2020. J Biol Chem. 295:1658. PubMed
  17. Leborgne NGF, et al. 2020. Front Immunol. 11:562587. PubMed
  18. Wang C, et al. 2020. Oncoimmunology. 9:1809947. PubMed
  19. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  20. Vitiello GA, et al. 2018. Clin Cancer Res. 24:972. PubMed
  21. Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed
  22. Bignon A, et al. 2017. Front Immunol. 0.722222222. PubMed
  23. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
  24. Goel S, et al. 2017. Nature. 548:471. PubMed
  25. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  26. Shi B, et al. 2018. J Immunol. 200:586. PubMed
  27. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  28. Mayer JU, et al. 2020. Front Immunol. 11:592325. PubMed
  29. Son YM, et al. 2020. Eur J Immunol. 50:1067. PubMed
  30. Nguyen N, et al. 2022. iScience. 25:103679. PubMed
  31. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  32. Schafflick D, et al. 2020. Nat Commun. 247:11. PubMed
  33. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  34. Tian D, et al. 2020. FASEB J. 34:3367. PubMed
  35. Delgobo M, et al. 2021. Front Immunol. 12:584538. PubMed
  36. Li W, et al. 2020. J Clin Invest. 130:6718. PubMed
  37. Hiramatsu-Asano S, et al. 2021. Front Immunol. 11:616141. PubMed
  38. Muhammad F, et al. 2020. Front Immunol. 975:11. PubMed
  39. Do DC, et al. 2019. JCI Insight. 4:e126832. PubMed
  40. Stebegg M, et al. 2019. Nat Commun. 2.113194444. PubMed
  41. Kaisar MMM, et al. 2018. PLoS Biol. 16:e2005504. PubMed
  42. Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed
  43. Guo Y, et al. 2008. Blood. 112:480. PubMed
  44. Lynn MA, et al. 2021. Cell Reports. 36(8):109564. PubMed
  45. Schuhmann MK, et al. 2021. J Neuroinflammation. 18:46. PubMed
  46. Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed
  47. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  48. Hua J, et al. 2018. Sci Rep. 5.235416667. PubMed
  49. Manni M, et al. 2018. Nat Immunol. 1.074305556. PubMed
  50. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  51. Lai JF, et al. 2020. J Allergy Clin Immunol. 146:1406. PubMed
  52. Vukman KV, et al. 2020. J Extracell Vesicles. 10:e12023. PubMed
  53. Brown IK, et al. 2021. PLoS Pathog. 17:e1009602. PubMed
  54. Yshii L, et al. 2022. Nat Immunol. 23:878. PubMed
  55. Chen X, et al. 2022. Front Immunol. 13:828319. PubMed
  56. Hsiao CC, et al. 2021. Cells. 10:. PubMed
  57. Dooley K, et al. 2021. Mol Ther. 29:1729. PubMed
  58. Umemoto T, et al. 2017. EMBO J. 36:2390. PubMed
  59. Godoy-Calderón MJ, et al. 2018. Oncotarget. 8:11370. PubMed
  60. Van De Velde LA, et al. 2017. J Biol Chem. 292:15:00. PubMed
  61. Chihara N, et al. 2018. Nature. 558:454. PubMed
  62. Shin J, et al. 2018. Diabetes. 67:1068. PubMed
  63. Park GY, et al. 2020. Immune Netw. e43:20. PubMed
  64. Sun Y, et al. 2020. J Immunol. 205:3358. PubMed
  65. Schuler CF, et al. 2020. Allergy. 75:2279. PubMed
  66. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  67. King IL, et al. 2017. Mucosal Immunol. 10:1160. PubMed
  68. Kälin S et al. 2017. Cell metabolism. 26(3):475-492 . PubMed
  69. Oyarce K, et al. 2018. Front Immunol. 9:112. PubMed
  70. Parigi SM, et al. 2018. Sci Rep. 0.440277778. PubMed
  71. Tan CL, et al. 2018. Immunohorizons. 0.248611111. PubMed
  72. Williams SK, et al. 2018. Sci Rep. 8:13628. PubMed
  73. Yoon BH, et al. 2018. Mol Cells. 41:953. PubMed
  74. Pasciuto E, et al. 2020. Cell. 182:625. PubMed
  75. Costa B, et al. 2021. Cancers (Basel). 13:00. PubMed
  76. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
  77. Li J, et al. 2021. Front Immunol. 12:710406. PubMed
  78. Seo SU, et al. 2021. Front Immunol. 12:697162. PubMed
  79. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  80. Schuhmann MK, et al. 2020. Circ Res. 127:1023. PubMed
  81. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  82. Kawabe T, et al. 2017. Sci Immunol. 2:eaam9315. PubMed
  83. Yi J, et al. 2019. Mol Cells. 42:228. PubMed
  84. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
  85. Takeuchi Y, et al. 2021. Sci Rep. 11:18679. PubMed
  86. Cui X, et al. 2017. J Immunol. 199:4066. PubMed
  87. Deng W et al. 2019. Cell reports. 27(6):1755-1768 . PubMed
  88. Lee YJ, et al. 2018. Front Microbiol. 9:83. PubMed
  89. Heinrich A, et al. 2020. Cell Rep. 31:107513. PubMed
  90. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  91. Udumula MP, et al. 2021. Mol Metab. 53:101272. PubMed
  92. Karuppuchamy T, et al. 2020. Inflamm Bowel Dis. 216:26. PubMed
  93. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
  94. Huppé CA, et al. 2018. Mucosal Immunol. 0.536111111. PubMed
  95. Rios–Doria J, et al. 2017. Cancer Res. 77:2686. PubMed
  96. Lee YJ, et al. 2018. FASEB J. 32:4658. PubMed
  97. Atif SM, et al. 2019. JCI Insight. 4:e125494. PubMed
  98. Khameneh HJ, et al. 2017. J Immunol. 198:196. PubMed
  99. Fritz Y, et al. 2017. J Invest Dermatol. 137:696. PubMed
  100. Regan–Komito D, et al. 2017. Front Immunol. 1.459027778. PubMed
RRID
AB_312708 (BioLegend Cat. No. 100505)
AB_312708 (BioLegend Cat. No. 100506)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD4
Specificity Alt (DOES NOT SHOW ON TDS):
CD4
App Abbreviation (DOES NOT SHOW ON TDS):
FC,CyTOF®,IHC-F,IHC
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 4    Revision Date: 10/02/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account